The European Medicines Agency (EMEA) says it is unlikely that cervical cancer vaccine Gardasil caused seizures and loss of consciousness in two girls given the agent in Spain.
The Spanish Ministry of Health temporarily withdrew a batch of the human papillomavirus vaccine developed by US drug major Merck & Co, following the emergence of two suspected cases of adverse events (Marketletter February 16).
The Ministry said that only the NH52670 batch was affected and the move was only a precaution. At the time, European distributor Sanofi Pasteur MSD stressed that both children had other medical conditions, which may have led to the adverse events.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze